Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 130.10 INR
Change Today +1.95 / 1.52%
Volume 321.4K
ASTEL On Other Exchanges
Symbol
Exchange
Natl India
As of 7:05 AM 04/28/15 All times are local (Market data is delayed by at least 15 minutes).

astec lifesciences ltd (ASTEL) Snapshot

Open
127.00
Previous Close
128.15
Day High
133.00
Day Low
122.20
52 Week High
04/15/15 - 172.70
52 Week Low
05/19/14 - 37.65
Market Cap
2.5B
Average Volume 10 Days
232.4K
EPS TTM
4.68
Shares Outstanding
19.5M
EX-Date
09/15/14
P/E TM
27.8x
Dividend
1.00
Dividend Yield
0.77%
Current Stock Chart for ASTEC LIFESCIENCES LTD (ASTEL)

Related News

No related news articles were found.

astec lifesciences ltd (ASTEL) Related Businessweek News

No Related Businessweek News Found

astec lifesciences ltd (ASTEL) Details

Astec LifeSciences Limited manufactures of agrochemicals and pharmaceutical intermediates in India. The company offers agrochemicals, such as tebuconazole, propiconazole, hexaconazole, difenoconazole, epoxiconazole, cyproconazole, flutriafol, tricyclazole, metalaxyl, and lambda cyhalothrin; and pharmaceutical intermediates, including 2’,4’-dichloroacetophenone, 2-chloro-4’-fluoro acetophenone, 4-methyl phthalic anhydride, and thio bis-4-chloro thymol. It is also involved in the sale of approximately 30 branded formulations that primarily comprise fungicides, herbicides, and insecticides. The company also serves customers in the Americas, Europe, Africa, the Middle East, and the Asia Pacific. Astec LifeSciences Limited was founded in 1994 and is based in Mumbai, India.

Founded in 1994

astec lifesciences ltd (ASTEL) Top Compensated Officers

Chairman, Managing Director and Member of Ris...
Total Annual Compensation: 4.8M
Whole Time Director
Total Annual Compensation: 944.0K
Compensation as of Fiscal Year 2014.

astec lifesciences ltd (ASTEL) Key Developments

Astec Denies Sales Rumor

The Exchange had sought clarification from Astec LifeSciences Limited (NSEI:ASTEC) with respect to news article appearing on ET NOW on March 11, 2015 titled "Company looking to sell stake, company open to selling-off business, bring in strategic partner". Astec replied stating "We remain fully committed to grow the operations of the company and are looking at a healthy growth this year. With regards to the clarification sought regarding sale of equity, we as per company policy do not comment on the market rumors and speculations. We have complied with all the regulatory requirements and no price sensitive information is concealed or pending to be intimated to Stock Exchanges as per clause 36 of the Listing Agreement that would impact the Companys performance or its stock price. All announcements are being disseminated by the Company to the Stock Exchanges from time to time."

Astec LifeSciences Limited, Board Meeting, Mar 05, 2015

Astec LifeSciences Limited, Board Meeting, Mar 05, 2015. Agenda: To consider re-appointment of Ashok V. Hiremath as Managing Director subject to the approval of members; and to consider re-appointment of Janak Rawal as Whole Time Director subject to the approval of members.

Astec LifeSciences Limited Announces Standalone and Consolidated Unaudited Earnings Results for the Third Quarter and Nine Months Ended December 31, 2014

Astec LifeSciences Limited announced standalone and consolidated unaudited earnings results for the third quarter and nine months ended December 31, 2014. For the quarter, the standalone company reported net sales of INR 530.195 million compared with INR 472.871 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 81.148 million compared with INR 59.339 million for the same period a year ago. Profit from ordinary activities before tax was INR 36.856 million compared with INR 25.612 million for the same period a year ago. Net profit was INR 37.362 million or INR 1.99 per basic and diluted share compared with INR 22.614 million or INR 1.22 per basic and diluted share for the same period a year ago. For the nine months, the standalone company reported net sales of INR 1,610.217 million compared with INR 1,474.897 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 243.014 million compared with INR 184.318 million for the same period a year ago. Profit from ordinary activities before tax was INR 155.474 million compared with INR 91.413 million for the same period a year ago. Net profit was INR 120.236 million or INR 6.58 per basic and diluted share compared with INR 73.462 million or INR 3.96 per basic and diluted share for the same period a year ago. For the quarter, the consolidated company reported net sales of INR 572.605 million compared with INR 506.994 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 82.061 million compared with INR 59.519 million for the same period a year ago. Profit from ordinary activities before tax was INR 45.913 million compared with INR 24.295 million for the same period a year ago. Net profit was INR 35.927 million or INR 1.91 per basic and diluted share compared with INR 21.3 million or INR 1.15 per basic and diluted share for the same period a year ago. For the nine months, the consolidated company reported net sales of INR 1,745.415 million compared with INR 1,603.559 million for the same period a year ago. Profit from operation before other income, finance cost and exceptional items was INR 247.012 million compared with INR 189.147 million for the same period a year ago. Profit from ordinary activities before tax was INR 150.758 million compared with INR 88.559 million for the same period a year ago. Net profit was INR 115.355 million or INR 6.31 per basic and diluted share compared with INR 70.608 million or INR 3.90 per basic and diluted share for the same period a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ASTEL:IN 130.10 INR +1.95

ASTEL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ASTEL.
View Industry Companies
 

Industry Analysis

ASTEL

Industry Average

Valuation ASTEL Industry Range
Price/Earnings 18.0x
Price/Sales 1.1x
Price/Book 1.9x
Price/Cash Flow 8.7x
TEV/Sales 0.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ASTEC LIFESCIENCES LTD, please visit www.astecls.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.